{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T17:04:32Z","timestamp":1758992672785,"version":"3.37.3"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Grant number 220211"],"award-info":[{"award-number":["Grant number 220211"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>This study aimed to predict the impacts of shorter duration treatment regimens for multidrug-resistant tuberculosis (MDR-TB) on both MDR-TB percentage among new cases and overall MDR-TB cases in the WHO Southeast Asia Region. A deterministic compartmental model was constructed to describe both the transmission of TB and the MDR-TB situation in the Southeast Asia region. The population-level impacts of short-course treatment regimens were compared with the impacts of conventional regimens. Multi-way analysis was used to evaluate the impact by varying programmatic factors (eligibility for short-course MDR-TB treatment, treatment initiation, and drug susceptibility test (DST) coverage). The model predicted that overall TB incidence will be reduced from 246 (95% credible intervals (CrI), 221\u2013275) per 100,000 population in 2020 to 239 (95% CrI, 215\u2013267) per 100,000 population in 2035, with a modest reduction of 2.8% (95% CrI, 2.7%\u20132.9%). Despite the slight reduction in overall TB infections, the model predicted that the MDR-TB percentage among newly notified TB infections will remain steady, with 2.4% (95% CrI, 2.1\u20132.9) in 2020 and 2.5% (95% CrI, 2.3\u20133.1) in 2035, using conventional MDR-TB treatment. With the introduction of short-course regimens to treat MDR-TB, the development of resistance can be slowed by 38.6% (95% confidence intervals (CI), 35.9\u201341.3) reduction in MDR-TB case number, and 37.6% (95% CI, 34.9\u201340.3) reduction in MDR-TB percentage among new TB infections over the 30-year period compared with the baseline using the standard treatment regimen. The multi-way analysis showed eligibility for short-course treatment and treatment initiation greatly influenced the impacts of short-course treatment regimens on reductions in MDR-TB cases and percentage resistance among new infections. Policies which promote the expansion of short-course regimens and early MDR-TB treatment initiation should be considered along with other interventions to tackle antimicrobial resistance in the region.<\/jats:p>","DOI":"10.1371\/journal.pone.0248846","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T17:42:44Z","timestamp":1616780564000},"page":"e0248846","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3731-7960","authenticated-orcid":true,"given":"Win Min","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiriya","family":"Mahikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pouplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saranath","family":"Lawpoolsri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa J.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9839-5359","authenticated-orcid":true,"given":"Wirichada","family":"Pan-Ngum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"pone.0248846.ref001","unstructured":"World Health Organization. Global tuberculosis report 2018. Geneva; 2018."},{"key":"pone.0248846.ref002","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2307\/2060979","article-title":"The contribution of medical measures to the decline of mortality from respiratory tuberculosis: an age-period-cohort model","volume":"19","author":"JJ Collins","year":"1982","journal-title":"Demography"},{"issue":"23","key":"pone.0248846.ref003","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"MT Gler","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0248846.ref004","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"AS Pym","year":"2016","journal-title":"Eur Respir J"},{"issue":"10","key":"pone.0248846.ref005","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","article-title":"High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses","volume":"18","author":"A Piubello","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"pone.0248846.ref006","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5588\/ijtld.14.0535","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"C Kuaban","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"pone.0248846.ref007","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20199-month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"KJ Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0248846.ref008","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1001\/jama.1986.03370120057023","article-title":"Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy","volume":"255","author":"DE Snider","year":"1986","journal-title":"JAMA"},{"key":"pone.0248846.ref009","unstructured":"World Health Organization. WHO Operational Handbook on Tuberculosis, Module 4: Treatment\u2014Drug-Resistant Tuberculosis Treatment 2020 [Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240006997."},{"key":"pone.0248846.ref010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/1745-6215-15-353","article-title":"Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial","volume":"15","author":"AJ Nunn","year":"2014","journal-title":"Trials"},{"issue":"13","key":"pone.0248846.ref011","first-page":"1201","volume":"380","author":"AJ Nunn","year":"2019","journal-title":"A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis"},{"issue":"9","key":"pone.0248846.ref012","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.5588\/ijtld.16.0142","article-title":"Ending tuberculosis by 2030: can we do it?","volume":"20","author":"AB Suthar","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"pone.0248846.ref013","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12916-016-0723-2","article-title":"Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan","volume":"14","author":"JM Trauer","year":"2016","journal-title":"BMC medicine"},{"issue":"3","key":"pone.0248846.ref014","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2213-2600(16)30423-4","article-title":"Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis","volume":"5","author":"EA Kendall","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"11","key":"pone.0248846.ref015","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/trstmh\/try091","article-title":"Delay before drug susceptibility testing among patients with presumptive multidrug-resistant tuberculosis in Gujarat, India","volume":"112","author":"HD Shewade","year":"2018","journal-title":"Transactions of The Royal Society of Tropical Medicine and Hygiene"},{"issue":"7","key":"pone.0248846.ref016","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/resp.13304","article-title":"Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment","volume":"23","author":"C Lange","year":"2018","journal-title":"Respirology"},{"issue":"3","key":"pone.0248846.ref017","doi-asserted-by":"crossref","first-page":"e0172748","DOI":"10.1371\/journal.pone.0172748","article-title":"MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis","volume":"12","author":"EA Kendall","year":"2017","journal-title":"PLOS ONE"},{"issue":"12","key":"pone.0248846.ref018","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(15)00458-0","article-title":"Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis","volume":"3","author":"EA Kendall","year":"2015","journal-title":"Lancet Respir Med"},{"key":"pone.0248846.ref019","unstructured":"Hartig F, Minunno F, Paul S. BayesianTools: General-Purpose MCMC and SMC Samplers and Tools for Bayesian Statistics. R package version 0.1.6. 2019 [Available from: https:\/\/github.com\/florianhartig\/BayesianTools."},{"key":"pone.0248846.ref020","unstructured":"Team RC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2017."},{"issue":"9","key":"pone.0248846.ref021","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v033.i09","article-title":"Solving Differential Equations in R: Package deSolve","volume":"1","author":"K Soetaert","year":"2010","journal-title":"Journal of Statistical Software"},{"key":"pone.0248846.ref022","unstructured":"Hartig. F, Minunno. F, Paul. S. BayesianTools: General-Purpose MCMC and SMC Samplers and Tools for Bayesian Statistics. R package version 0.1.7. 2019."},{"key":"pone.0248846.ref023","unstructured":"World Health Organisation. The Shorter MDR-TB Regimen, 2016. http:\/\/wwwwhoint\/tb\/Short_MDR_regimen_factsheetpdf (Accessed 12 August 2016)."},{"issue":"2","key":"pone.0248846.ref024","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/ije\/28.2.327","article-title":"Interpreting the decline in tuberculosis: the role of secular trends in effective contact","volume":"28","author":"E Vynnycky","year":"1999","journal-title":"Int J Epidemiol"},{"issue":"3","key":"pone.0248846.ref025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2213-2600(16)30423-4","article-title":"Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis","volume":"5","author":"EA Kendall","year":"2017","journal-title":"The Lancet Respiratory medicine"},{"issue":"1","key":"pone.0248846.ref026","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1183\/09031936.00070812","article-title":"Contact investigation for tuberculosis: a systematic review and meta-analysis","volume":"41","author":"GJ Fox","year":"2013","journal-title":"The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology"},{"issue":"3","key":"pone.0248846.ref027","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1164\/rccm.200909-1355OC","article-title":"Revisiting rates of reactivation tuberculosis: a population-based approach","volume":"182","author":"CR Horsburgh","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"pone.0248846.ref028","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1128\/JCM.02116-16","article-title":"Whole-Genome Sequencing of Mycobacterium tuberculosis Provides Insight into the Evolution and Genetic Composition of Drug-Resistant Tuberculosis in Belarus","volume":"55","author":"KR Wollenberg","year":"2017","journal-title":"J Clin Microbiol"},{"issue":"3","key":"pone.0248846.ref029","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1473-3099(18)30673-X","article-title":"Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study","volume":"19","author":"K Z\u00fcrcher","year":"2019","journal-title":"The Lancet Infectious diseases"},{"issue":"3","key":"pone.0248846.ref030","article-title":"Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study","volume":"53","author":"F Sun","year":"2019","journal-title":"The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology"},{"issue":"20","key":"pone.0248846.ref031","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMc1505196","article-title":"Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis","volume":"373","author":"GV Bloemberg","year":"2015","journal-title":"The New England journal of medicine"},{"key":"pone.0248846.ref032","article-title":"Delamanid resistance: update and clinical management","author":"TVA Nguyen","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"pone.0248846.ref033","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/cid\/ciu674","article-title":"Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy","volume":"59","author":"G Narendran","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"8","key":"pone.0248846.ref034","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1473-3099(19)30307-X","article-title":"Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling","volume":"19","author":"GM Knight","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"pone.0248846.ref035","doi-asserted-by":"crossref","first-page":"l5894","DOI":"10.1136\/bmj.l5894","article-title":"Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study","volume":"367","author":"MC Becerra","year":"2019","journal-title":"Bmj"},{"issue":"1","key":"pone.0248846.ref036","doi-asserted-by":"crossref","first-page":"18099","DOI":"10.1038\/s41598-019-54561-9","article-title":"Projecting the impact of variable MDR-TB transmission efficiency on long-term epidemic trends in South Africa and Vietnam","volume":"9","author":"PP Salvatore","year":"2019","journal-title":"Scientific reports"},{"key":"pone.0248846.ref037","doi-asserted-by":"crossref","first-page":"l5894","DOI":"10.1136\/bmj.l5894","article-title":"Transmissibility and potential for disease progression of drug resistant &lt;em&gt;Mycobacterium tuberculosis&lt;\/em&gt;: prospective cohort study","volume":"367","author":"MC Becerra","year":"2019","journal-title":"Bmj"},{"issue":"40","key":"pone.0248846.ref038","article-title":"Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007","volume":"18","author":"LF Anderson","year":"2013","journal-title":"Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin"},{"issue":"13","key":"pone.0248846.ref039","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis","volume":"380","author":"AJ Nunn","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"pone.0248846.ref040","first-page":"413","article-title":"High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000\u20132003","volume":"14","author":"JC Brust","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"pone.0248846.ref041","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MJT.0b013e3181dd60ec","article-title":"Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases","volume":"18","author":"P Tabarsi","year":"2011","journal-title":"Am J Ther"},{"issue":"14","key":"pone.0248846.ref042","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1073\/pnas.140102797","article-title":"Criteria for the control of drug-resistant tuberculosis","volume":"97","author":"C Dye","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"pone.0248846.ref043","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1086\/655892","article-title":"Recurrence after Treatment for Pulmonary Multidrug-Resistant Tuberculosis","volume":"51","author":"MC Becerra","year":"2010","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"pone.0248846.ref044","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/cid\/cis1008","article-title":"Aggressive Regimens for Multidrug-Resistant Tuberculosis Reduce Recurrence","volume":"56","author":"MF Franke","year":"2013","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"pone.0248846.ref045","doi-asserted-by":"crossref","first-page":"e10799","DOI":"10.1371\/journal.pone.0010799","article-title":"Follow-Up of Patients with Multidrug Resistant Tuberculosis Four Years after Standardized First-Line Drug Treatment","volume":"5","author":"GX He","year":"2010","journal-title":"PLOS ONE"},{"issue":"17","key":"pone.0248846.ref046","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1097\/QAD.0b013e32835958ed","article-title":"The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting","volume":"26","author":"RM Houben","year":"2012","journal-title":"Aids"},{"key":"pone.0248846.ref047","unstructured":"WHO. Global tuberculosis control: WHO report 2016. Geneva: World Health Organization."},{"issue":"9","key":"pone.0248846.ref048","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/tmi.12534","article-title":"National tuberculosis prevalence surveys in Asia, 1990\u20132012: an overview of results and lessons learned","volume":"20","author":"I Onozaki","year":"2015","journal-title":"Trop Med Int Health"},{"issue":"1","key":"pone.0248846.ref049","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1371\/journal.pmed.0040022","article-title":"Epidemiology of Tuberculosis in a High HIV Prevalence Population Provided with Enhanced Diagnosis of Symptomatic Disease","volume":"4","author":"EL Corbett","year":"2007","journal-title":"PLOS Medicine"},{"issue":"4","key":"pone.0248846.ref050","doi-asserted-by":"crossref","first-page":"e17601","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"EW Tiemersma","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"pone.0248846.ref051","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/cid\/ciu186","article-title":"The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study","volume":"58","author":"FM Marx","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0248846.ref052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"EW Tiemersma","year":"2011","journal-title":"PloS one"},{"issue":"8","key":"pone.0248846.ref053","first-page":"1005","article-title":"Survival and Predictors of Death after Successful Treatment among Smear Positive Tuberculosis: A Cohort Study","volume":"5","author":"M Moosazadeh","year":"2014","journal-title":"Int J Prev Med"},{"issue":"5","key":"pone.0248846.ref054","first-page":"389","article-title":"The annual risk of infection with Mycobacterium tuberculosis in England and Wales since 1901","volume":"1","author":"E Vynnycky","year":"1997","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T17:43:38Z","timestamp":1616780618000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248846"}},"subtitle":[],"editor":[{"given":"Rebecca Lee","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0248846","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,3,26]]}}}